$WALDJun 1, 2026, 10:59 AMAI processed
Waldencast to sell Obagi Medical to Bridgepoint for up to $460M
AI Summary
Waldencast (WALD) agreed to sell 100% of Obagi Medical to Bridgepoint for an enterprise value of up to $460 million, with closing expected in Q3 2026 subject to customary regulatory approvals and purchase-price adjustments. The company intends to use proceeds to repay about $178 million of senior secured term debt and refocus on growing Milk Makeup, while founders Michel Brousset and Hind Sebti will transition to lead Obagi with Bridgepoint.
Positives
- Deal values Obagi Medical at up to $460M enterprise value
- Proceeds expected to repay ~ $178M of senior secured term loan, materially strengthening the balance sheet
- Transaction unanimously approved by disinterested board members and is not subject to a financing condition or shareholder vote
Negatives
- Purchase price is subject to customary net debt, working capital adjustments and contingent future payments
- Closing depends on regulatory approvals and other customary conditions; deal could fail or be delayed
- Sale narrows Waldencast to primarily Milk Makeup, reducing brand/diversification within the company